Cervical determinants of anal HPV infection and high-grade anal lesions in women: a collaborative pooled analysis

Cervical determinants of anal HPV infection and high-grade anal lesions in women: a collaborative pooled analysis
复制标题

DOI:
10.1016/s1473-3099(19)30164-1
复制
发表时间:
2019-08-01
影响因子:
56.3
通讯作者:
Clifford, Gary M.
Clifford, Gary M.
中科院分区:
医学1区
文献类型:
--
作者:
Lin, Chunqing;Slama, Jiri;Clifford, Gary M.

文献摘要

被引文献

相似文献

背景宫颈癌筛查可能有助于预防女性肛门癌。我们的目的是调查,如果常规宫颈癌筛查结果,即高危型人乳头瘤病毒(HPV)感染和细胞组织病理学预测肛门HPV 16感染,肛门高级鳞状上皮内病变(HSIL),因此,anal cancer.Methods我们做了一个系统的审查MEDLINE,Embase和科克伦图书馆的研究肛门HPV和HSIL的宫颈决定因素发表到2018年8月31日。我们集中重新分析了来自36项研究的13427名妇女的配对宫颈和肛门样本的个人水平数据。我们使用患病率(PR)和95%CI,按艾滋病毒状态、宫颈高危HPV、宫颈细胞组织病理学、年龄及其组合比较了肛门高危HPV的患病率。在3255名女性肛门细胞病理学结果,PR同样计算所有肛门HSIL和HPV 16阳性肛门HSIL.Findings宫颈和肛门HPV感染高度相关。在HIV阴性的妇女中,宫颈HPV 16阳性的肛门HPV 16感染率为41%(447/1097),宫颈HPV 16阴性的肛门HPV 16感染率为2%(214/8663)(PR 16.5,95%CI 14.2-19.2,p
Background Cervical cancer screening might contribute to the prevention of anal cancer in women. We aimed to investigate if routine cervical cancer screening results-namely high-risk human papillomavirus (HPV) infection and cytohistopathology-predict anal HPV16 infection, anal high-grade squamous intraepithelial lesions (HSIL) and, hence, anal cancer.Methods We did a systematic review of MEDLINE, Embase, and the Cochrane library for studies of cervical determinants of anal HPV and HSIL published up to Aug 31, 2018. We centrally reanalysed individual-level data from 13 427 women with paired cervical and anal samples from 36 studies. We compared anal high-risk HPV prevalence by HIV status, cervical high-risk HPV, cervical cytohistopathology, age, and their combinations, using prevalence ratios (PR) and 95% CIs. Among 3255 women with anal cytohistopathology results, PRs were similarly calculated for all anal HSIL and HPV16-positive anal HSIL.Findings Cervical and anal HPV infections were highly correlated. In HIV-negative women, anal HPV16 prevalence was 41% (447/1097) in cervical HPV16-positive versus 2% (214/8663) in cervical HPV16-negative women (PR 16.5, 95% CI 14.2-19.2, p